Logo image of NURS.CA

HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis

Canada - TSX-V:NURS - CA44877L1013 - Common Stock

4.12 CAD
+0.07 (+1.73%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to NURS. NURS was compared to 9 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for NURS as it has an excellent financial health rating, but there are worries on the profitability. NURS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NURS has reported negative net income.
In the past year NURS had a positive cash flow from operations.
NURS.CA Yearly Net Income VS EBIT VS OCF VS FCFNURS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

NURS has a Return On Assets of -0.91%. This is in the better half of the industry: NURS outperforms 77.78% of its industry peers.
NURS's Return On Equity of -2.40% is fine compared to the rest of the industry. NURS outperforms 77.78% of its industry peers.
Industry RankSector Rank
ROA -0.91%
ROE -2.4%
ROIC N/A
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NURS.CA Yearly ROA, ROE, ROICNURS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Gross Margin of NURS (34.69%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NURS has declined.
NURS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
NURS.CA Yearly Profit, Operating, Gross MarginsNURS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

NURS does not have a ROIC to compare to the WACC, probably because it is not profitable.
NURS has more shares outstanding than it did 1 year ago.
NURS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NURS.CA Yearly Shares OutstandingNURS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
NURS.CA Yearly Total Debt VS Total AssetsNURS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M

2.2 Solvency

NURS has an Altman-Z score of 22.97. This indicates that NURS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NURS (22.97) is better than 88.89% of its industry peers.
NURS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 22.97
ROIC/WACCN/A
WACC9.03%
NURS.CA Yearly LT Debt VS Equity VS FCFNURS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 -500K -1M -1.5M

2.3 Liquidity

NURS has a Current Ratio of 1.50. This is a normal value and indicates that NURS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of NURS (1.50) is better than 66.67% of its industry peers.
A Quick Ratio of 1.50 indicates that NURS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.50, NURS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
NURS.CA Yearly Current Assets VS Current LiabilitesNURS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

8

3. Growth

3.1 Past

NURS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.24%, which is quite impressive.
The Revenue has grown by 37.23% in the past year. This is a very strong growth!
The Revenue has been growing by 137.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)96.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.17%
Revenue 1Y (TTM)37.23%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%34.42%

3.2 Future

The Earnings Per Share is expected to grow by 279.00% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 131.82% on average over the next years. This is a very strong growth
EPS Next Y974.04%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue Next Year274.18%
Revenue Next 2Y194.65%
Revenue Next 3Y131.82%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NURS.CA Yearly Revenue VS EstimatesNURS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NURS.CA Yearly EPS VS EstimatesNURS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Forward Earnings ratio of 14.57 indicates a correct valuation of NURS.
Based on the Price/Forward Earnings ratio, NURS is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of NURS to the average of the S&P500 Index (23.32), we can say NURS is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 14.57
NURS.CA Price Earnings VS Forward Price EarningsNURS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

NURS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. NURS is cheaper than 77.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5148.9
EV/EBITDA N/A
NURS.CA Per share dataNURS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NURS's earnings are expected to grow with 279.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y440.3%
EPS Next 3Y279.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NURS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYDREIGHT TECHNOLOGIES INC

TSX-V:NURS (10/3/2025, 7:00:00 PM)

4.12

+0.07 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-25 2025-08-25/amc
Earnings (Next)11-24 2025-11-24
Inst Owners0.28%
Inst Owner ChangeN/A
Ins Owners2.14%
Ins Owner ChangeN/A
Market Cap192.57M
Analysts80
Price Target8.67 (110.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.25%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)12.5%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.86%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.57
P/S 11.19
P/FCF 5148.9
P/OCF 140.34
P/B 61.15
P/tB 142.93
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.28
Fwd EY6.86%
FCF(TTM)0
FCFY0.02%
OCF(TTM)0.03
OCFY0.71%
SpS0.37
BVpS0.07
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.91%
ROE -2.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.69%
FCFM 0.22%
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score5
Asset Turnover2.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 706.24%
Cap/Sales 7.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z 22.97
F-Score5
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.17%
EPS Next Y974.04%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue 1Y (TTM)37.23%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%34.42%
Revenue Next Year274.18%
Revenue Next 2Y194.65%
Revenue Next 3Y131.82%
Revenue Next 5YN/A
EBIT growth 1Y91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1245.74%
EBIT Next 3Y347.79%
EBIT Next 5YN/A
FCF growth 1Y106.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y324.95%
OCF growth 3YN/A
OCF growth 5YN/A